Search Page

1

Cite

Share

Immunohistochemistry and quantitative analysis of protein expression.

Cregger M, Berger AJ, Rimm DL. Cregger M, et al. Arch Pathol Lab Med. 2006 Jul;130(7):1026-30. doi: 10.5858/2006-130-1026-IAQAOP. Arch Pathol Lab Med. 2006. PMID: 16831029 Free article. Review.

Cite

Share

2

Cite

Share

Analytic variability in immunohistochemistry biomarker studies.

Anagnostou VK, Welsh AW, Giltnane JM, Siddiqui S, Liceaga C, Gustavson M, Syrigos KN, Reiter JL, Rimm DL. Anagnostou VK, et al. Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):982-91. doi: 10.1158/1055-9965.EPI-10-0097. Epub 2010 Mar 23. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20332259 Free PMC article.

Cite

Share

3

Cite

Share

Automated analysis of tissue microarrays.

Dolled-Filhart M, Gustavson M, Camp RL, Rimm DL, Tonkinson JL, Christiansen J. Dolled-Filhart M, et al. Methods Mol Biol. 2010;664:151-62. doi: 10.1007/978-1-60761-806-5_15. Methods Mol Biol. 2010. PMID: 20690061

Cite

Share

4

Cite

Share

Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.

Nadler Y, González AM, Camp RL, Rimm DL, Kluger HM, Kluger Y. Nadler Y, et al. Ann Oncol. 2010 Mar;21(3):466-473. doi: 10.1093/annonc/mdp346. Epub 2009 Aug 28. Ann Oncol. 2010. PMID: 19717535 Free PMC article.

Cite

Share

5

Cite

Share

Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast cancer.

Sullivan CA, Ghosh S, Ocal IT, Camp RL, Rimm DL, Chung GG. Sullivan CA, et al. Hum Pathol. 2009 Feb;40(2):156-65. doi: 10.1016/j.humpath.2008.07.005. Epub 2008 Sep 16. Hum Pathol. 2009. PMID: 18799189

Cite

Share

6

Cite

Share

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells.

Agarwal S, Zerillo C, Kolmakova J, Christensen JG, Harris LN, Rimm DL, Digiovanna MP, Stern DF. Agarwal S, et al. Br J Cancer. 2009 Mar 24;100(6):941-9. doi: 10.1038/sj.bjc.6604937. Epub 2009 Feb 24. Br J Cancer. 2009. PMID: 19240716 Free PMC article.

Cite

Share

7

Cite

Share

In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis.

Neumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL. Neumeister V, et al. Am J Pathol. 2010 May;176(5):2131-8. doi: 10.2353/ajpath.2010.090712. Epub 2010 Mar 12. Am J Pathol. 2010. PMID: 20228222 Free PMC article.

Cite

Share

8

Cite

Share

Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome.

Harigopal M, Heymann J, Ghosh S, Anagnostou V, Camp RL, Rimm DL. Harigopal M, et al. Breast Cancer Res Treat. 2009 May;115(1):77-85. doi: 10.1007/s10549-008-0063-9. Epub 2008 Jun 3. Breast Cancer Res Treat. 2009. PMID: 18521745

Cite

Share

9

Cite

Share

Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.

Giltnane JM, Molinaro A, Cheng H, Robinson A, Turbin D, Gelmon K, Huntsman D, Rimm DL. Giltnane JM, et al. Arch Pathol Lab Med. 2008 Oct;132(10):1635-47. doi: 10.5858/2008-132-1635-COQIWC. Arch Pathol Lab Med. 2008. PMID: 18834223 Free article.

Cite

Share

10

Cite

Share

Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.

Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL; American Society of Clinical Oncology; College of American Pathologists. Moeder CB, et al. J Clin Oncol. 2007 Dec 1;25(34):5418-25. doi: 10.1200/JCO.2007.12.8033. J Clin Oncol. 2007. PMID: 18048824

Cite

Share